Form 4 for INMB Inmune Bio, Inc.
Accepted 2021-08-27 00:00:00 ET · period of report 2021-08-25 · accession 0001213900-21-045373 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-27 | 2021-08-25 | INMB | Tesi Raymond Joseph | Pres, CEO, Dir, 10% | M - OptEx | $3.91 | +30.0K | 1.52M | +2% | +$117.3K |
| D | 2021-08-27 | 2021-08-25 | INMB | Tesi Raymond Joseph | Pres, CEO, Dir, 10% | M - OptEx | $0.00 | -30.0K | 270.0K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-25 | M | A | 30,000 | $3.91 | 1,524,433 | D | — | — | (F1) These options were exercised in a cash transaction by the Reporting Person under Rule 16(b)(3). The options were granted to the Reporting Person under the Company's 2019 Stock Incentive Plan. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2021-08-25 | M | D | 30,000 | $0.00 | 270,000 | D | $3.91 · — to 2029-11-24 | 30,000 Common Stock | (F1) These options were exercised in a cash transaction by the Reporting Person under Rule 16(b)(3). The options were granted to the Reporting Person under the Company's 2019 Stock Incentive Plan. |